Shots:
- Dong-A ST received EC approval for Imuldosa (DMB-3115), a biosimilar of Janssen’s Stelara (Ustekinumab), following CHMP’s positive opinion & FDA’s approval
- Imuldosa, initially developed by Dong-A Socio Holdings & Meiji Seika Pharma, & was transferred to Dong-A ST in 2020 for global development and commercialization. In 2021, it was out-licensed to Intas Pharmaceuticals for launch through subsidiaries, incl. Accord Biopharma (US) and Accord Healthcare (Europe, UK, Canada)
- Ustekinumab is a fully human anti-IL-12/IL-23 mAb indicated for the treatment of plaque psoriasis, psoriatic arthritis, & Crohn’s disease
Ref: Dong-A ST | Image: Dong-A ST| Press Release
Related News:- Bio-Thera Solutions and Tabuk Pharmaceuticals Join Forces to Commercialize BAT2206 (Biosimilar, Stelara) in Saudi Arabia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
